Dose Insider / Glossary / MASH and MASLD

MASLD and MASHThe new names for fatty liver disease, and what GLP-1 drugs do

Updated November 20, 2026 路 3 min read 路 Rinella 2023 nomenclature consensus; ESSENCE trial 2025; Wegovy label; SYNERGY-NASH

MASLD, metabolic dysfunction-associated steatotic liver disease, is the name chosen in 2023 for what used to be called nonalcoholic fatty liver disease, or NAFLD. MASH, metabolic dysfunction-associated steatohepatitis, replaced NASH for its inflamed form.1 Semaglutide now has an approved use in MASH: the Wegovy label includes adults with noncirrhotic MASH and moderate to advanced liver fibrosis.2

62.9%MASH resolved, Semaglutide 2.4 mg, liver results at week 72
Liver results at week 72ESSENCE trial, % of people, by liver biopsyMASH RESOLVEDSemaglutide 2.4 mg62.9%Placebo34.3%FIBROSIS IMPROVEDSemaglutide 2.4 mg36.8%Placebo22.4%Liver results at week 72ESSENCE trial, % of people, by liver biopsyMASH RESOLVEDSemaglutide 2.4 mg62.9%Placebo34.3%FIBROSIS IMPROVEDSemaglutide 2.4 mg36.8%Placebo22.4%

Both without the other measure getting worse.

On this page

Why the names changed

The change came from a consensus process led by three large liver associations, with 236 panelists from 56 countries. The old terms had two problems: they defined the disease by what it was not, and they used words seen as stigmatizing. 74% of respondents thought the old names flawed enough to change; 61% found "nonalcoholic" stigmatizing and 66% "fatty". Agreement required a 67% supermajority, and an independent committee made the final choice of name and criteria. The panel kept steatohepatitis as a term, judging it an important concept of how the disease works.1

Multisociety Delphi consensus, 2023.1

The authors describe the new names as widely supported and free of stigma, and expect them to improve awareness of the disease and the identification of patients who have it.1

What semaglutide did in ESSENCE

ESSENCE is a phase 3 trial of semaglutide 2.4 mg a week against placebo, published in the New England Journal of Medicine in 2025. It enrolled 1,197 people with MASH confirmed by liver biopsy and fibrosis of stage 2 or 3, two on semaglutide for every one on placebo, and is planned to run for 240 weeks. The first results, from 800 people at week 72, were:3

The difference in MASH resolution was 28.7 percentage points, with a range from 21.1 to 36.2. Bodily pain scores did not differ between the groups, and stomach and gut side effects were more common on semaglutide.3 The Wegovy label approves the MASH use under accelerated approval, based on these improvements in MASH and fibrosis; keeping it may depend on a confirmatory trial showing clinical benefit.2

Liver fat itself

Liver fat can also be measured without a biopsy. In SURPASS-3 MRI, 296 adults with type 2 diabetes had liver fat measured by MRI before and after 52 weeks. Liver fat started at an average of 15.71% of the liver and fell by 8.09 percentage points on tirzepatide 10 or 15 mg, against 3.38 on insulin degludec.4 Fat on a scan is not the same as MASH on a biopsy, which also looks for inflammation and scarring.

Other GLP-1-based drugs in MASH

Tirzepatide was tested in the phase 2 SYNERGY-NASH trial, where MASH resolved without worse scarring in 44% to 62% of people across its doses, against 10% on placebo, at week 52.5 Pemvidutide, which acts on the GLP-1 and glucagon receptors, resolved MASH in 58% of people on its 1.2 mg dose at 24 weeks in a phase 2b trial.6 Both were phase 2 trials funded by the companies that make the drugs, and pemvidutide's was named IMPACT. Neither drug has an approved MASH use yet.

Sources

  1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-1556. doi:10.1016/j.jhep.2023.06.003
  2. WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; sections 1 and 14.4. dailymed.nlm.nih.gov
  3. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089-2099. doi:10.1056/NEJMoa2413258
  4. Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393-406. doi:10.1016/S2213-8587(22)00070-5
  5. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024;391:299-310. Funded by Eli Lilly; NCT04166773. doi:10.1056/NEJMoa2401943
  6. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet 2025;406:2644-2655. Funded by Altimmune; NCT05989711. doi:10.1016/S0140-6736(25)02114-2

Related analyses

Log liver test results and weight together, so your doctor sees both trends side by side.

Open Dose Insider